A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
Paxceed™ is being developed by Angiotech Pharmaceuticals, Inc. for the treatment of
Rheumatoid Arthritis (RA). The main objective of this study is to determine the effectiveness
of treatment with Paxceed™ in patients with RA. In RA, there is an increase in cell growth
and changes in cell function. The active substance in Paxceed™, paclitaxel, has undergone
clinical studies as a cancer chemotherapeutic agent and has demonstrated its usefulness as an
agent that stops growth of cells and blocks certain types of cell function associated with
RA. Because of these effects, it is thought that Paxceed™ might alter the destructive course
of RA.